Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Heba Aref, Sherin Hammad, Khaled M Darwish, Mohamed S Elgawish
The linagliptin (LIN) and pioglitazone HCl (PIO) combination, currently undergoing phase III clinical trials for diabetes mellitus treatment, demonstrated significant improvements in glycemic control. However, the absence of an analytical method for simultaneous determination in biological fluids highlights a crucial gap. This underscores the pressing need for sensitive bioanalytical methods, emphasizing the paramount importance of developing such tools to advance diabetes management strategies and enhance patient care...
April 29, 2024: Chemical Research in Toxicology
#2
JOURNAL ARTICLE
Ji-Yeon Park, Joonyub Lee, Yoon-Hee Choi, Kyung Wan Min, Kyung Ah Han, Kyu Jeung Ahn, Soo Lim, Young-Hyun Kim, Chul Woo Ahn, Kyung Mook Choi, Kun-Ho Yoon
BACKGROUND: Guidelines for switching to triple combination therapy directly after monotherapy failure are limited. This study investigated the efficacy, long-term sustainability, and safety of either mono or dual add-on therapy using alogliptin and pioglitazone for patients with type 2 diabetes mellitus (T2DM) who did not achieve their target glycemic range with metformin monotherapy. METHODS: The Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) was a multicenter, placebo-controlled, double-blind, randomized trial...
April 23, 2024: Diabetes & Metabolism Journal
#3
JOURNAL ARTICLE
Dipika Bansal, Beema T Yoosuf, Muhammed Favas Kt, Pinaki Dutta
BACKGROUND: Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) have acquired a foothold in managing type 2 diabetes mellitus, but few concerns have arisen regarding their overall safety profile. The aim of this study is to assess the potential risk of DPP-4 inhibitors by analyzing data from the FDA Adverse Event Reporting System (FAERS) database. RESEARCH DESIGN AND METHODS: This is a retrospective study which explored the FAERS database till March 2023 for the collection of safety reports...
April 16, 2024: Expert Opinion on Drug Safety
#4
JOURNAL ARTICLE
Sheikh Sunzid Ahmed, M Oliur Rahman
Addition to the angiosperm flora provides essential insights into the biodiversity of a region, contributing to ecological understanding and conservation planning. Gafargaon subdistrict under Mymensingh district in Bangladesh represents a diverse population of angiosperms with a multifaceted ecosystem that demands re-evaluation of the existing angiosperm diversity of Gafargaon to update the status of angiosperm taxa and facilitate their conservation efforts. With this endeavor, a total of 100 angiosperm taxa belonging to 90 genera and 46 families were uncovered as additional occurrence in Gafargaon...
2024: PloS One
#5
REVIEW
Kashif Rahim, Muhammad Shan, Ihtisham Ul Haq, Muhammad Naveed Nawaz, Sajida Maryam, Mansour S Alturki, Abdulaziz H Al Khzem, Kamel Metwally, Simona Cavalu, Saleh F Alqifari, Galal Yahya
DPP4 (Dipeptidyl-peptidase 4) a versatile protease, emerges as a prominent player in soluble and membrane-bound forms. Its heightened expression has been intimately linked to the initiation and severity of diverse autoimmune diseases, spanning rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (SSc), inflammatory bowel disease, autoimmune diabetes, and even SARS-CoV-2 infection. Operating as a co-stimulator of T cell activity, DPP4 propels T cell proliferation by binding adenosine deaminase (ADA), thereby augmenting the breakdown of adenosine-an influential inhibitor of T cell proliferation...
2024: Journal of Inflammation Research
#6
REVIEW
Jarin Tasnim, Najihah Mohd Hashim, Heh Choon Han
A drug interaction is a condition in which two or more drugs are taken at the same time. Type 2 diabetes mellitus is a significant contributor to polypharmacy. Proton pump inhibitors (PPIs) are often prescribed in combination with metformin or DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) or a combined dose of metformin and DPP-4 inhibitor to treat gastritis in diabetic patients. This review article mainly focused on evaluating the potential drug-drug interactions (DDIs) between PPIs (i...
March 2024: Cell Biochemistry and Function
#7
JOURNAL ARTICLE
Nynne Sophie Holdt-Caspersen, Claus Dethlefsen, Peter Vestergaard, Ole Hejlesen, Stine Hangaard, Morten Hasselstrøm Jensen
The adherence to oral antidiabetic drugs (OADs) among people with type 2 diabetes (T2D) is suboptimal. However, new OADs have been marketed within the last 10 years. As these new drugs differ in mechanism of action, treatment complexity, and side effects, they may influence adherence. Thus, the aim of this study was to assess the adherence to newer second-line OADs, defined as drugs marketed in 2012-2022, among people with T2D. A systematic review was performed in CINAHL, Cochrane Trials, Embase, PubMed, PsycINFO, and Scopus...
April 2024: Pharmacology Research & Perspectives
#8
JOURNAL ARTICLE
Sandy R Botros, Asmaa I Matouk, Amr Amin, Gehan H Heeba
Introduction: Nephrotoxicity represents a major complication of using doxorubicin (DOX) in the management of several types of cancers. Increased oxidative stress and the activation of inflammatory mediators play outstanding roles in the development of DOX-induced kidney damage. This study aimed to investigate whether the two pathways of incretin-based therapy, glucagon-like peptide-1 receptor agonist (presented as semaglutide, SEM) and dipeptidyl peptidase-4 inhibitor (presented as alogliptin, ALO), differentially protect against DOX-induced nephrotoxicity in rats and to clarify the underlying molecular mechanisms...
2024: Frontiers in Pharmacology
#9
JOURNAL ARTICLE
Jaquellyne Gurgel Penaforte-Saboia, Carlos Eduardo Barra Couri, Natasha Vasconcelos Albuquerque, Lana Livia Peixoto Linard, Daniel Autran Cavalcante Araújo, Sherida Karanini Paz de Oliveira, Thisciane Ferreira Pinto Gomes, Marcelo Maia Pinheiro, Maria Helane Costa Gurgel Castelo, Virgínia Oliveira Fernandes, Renan Magalhães Montenegro Júnior
BACKGROUND: The incidence of Type 1 Diabetes Mellitus (T1DM) is on the rise. Since there is no curative treatment, it is urgent to look for therapies that can delay disease progression and protect pancreatic β-cells. Dipeptidyl peptidase-4 inhibitors (DPP-4i) have shown potential in modulating inflammation and preventing β-cell destruction. This protocol describes an upcoming trial to evaluate the effectiveness of the DPP-4i alogliptin in delaying the progression of stage 2 (presymptomatic) to stage 3 (symptomatic) T1DM...
2024: Diabetes, Metabolic Syndrome and Obesity
#10
JOURNAL ARTICLE
Sathish Dharani, Eman M Mohamed, Ziyaur Rahman, Mansoor A Khan
Between February 2020 and January 2022, the Food and Drug Administration (FDA) recalled 281 metformin extended-release products due to the presence of N-nitrosodimethylamine (NDMA) above the acceptable daily intake (ADI, 96 ng/day). Our previous studies indicated presence of NDMA levels above ADI in both metformin immediate and extended-release products. When metformin products have NDMA impurities, it is indispensable to check for the same impurities in metformin combination products. Therefore, the objective of the present study was to evaluate in-use stability of commercial metformin combination products for NDMA...
January 24, 2024: AAPS PharmSciTech
#11
REVIEW
Marzieh Daniali, Shekoufeh Nikfar, Mohammad Abdollahi
INTRODUCTION: This study compares diabetes management between pediatric and adult patients and identifies treatment challenges and gaps. AREAS COVERED: We searched PubMed and Clinicaltrails.gov databases for studies published from 2001 to 2023 on diabetes management in different age groups. EXPERT OPINION: Research shows children have lower insulin sensitivity, clearance, and β cell function than adults. The US FDA only allows insulin, metformin, and liraglutide as antidiabetic medication options for children...
2024: Expert Review of Endocrinology & Metabolism
#12
JOURNAL ARTICLE
Amir Razaghizad, Haya Aziz, Guang K Zhang, João Pedro Ferreira, William B White, Cyrus R Mehta, George L Bakris, Faiez Zannad, Abhinav Sharma
BACKGROUND: Therapies can reduce the risk of heart failure (HF) development and progression in type 2 diabetes (T2D); nevertheless, the risk of these outcomes is greater in females than in males. METHODS: To investigate sex-differences in HF development and progression, we compared baseline circulating proteins (Olink® Cardiovascular II panel) in males and females with T2D and recent acute coronary syndrome (ACS) for the outcome of heart failure hospitalization (HFH)...
November 6, 2023: Journal of Cardiac Failure
#13
Nicholas Lepore, Taya Carpenter, Alan Wolff
Angioedema is a rare but potentially life-threatening complication associated with angiotensin-converting enzyme (ACE) inhibitors. Although the pathophysiology is well understood, cases involving the concurrent use of other medications are less explored. We present a unique case of ACE inhibitor-induced angioedema in a 57-year-old male, which developed soon after receiving intravenous contrast. The patient's medication list included a dipeptidyl peptidase-IV inhibitor and a calcium channel blocker. Studies have shown an increased risk of angioedema with the combined use of these medications, likely due to alterations in bradykinin metabolism...
September 2023: Curēus
#14
RANDOMIZED CONTROLLED TRIAL
Mingtong Xu, Kan Sun, Wenjie Xu, Chuan Wang, Dewen Yan, Shu Li, Li Cong, Yinzhen Pi, Weihong Song, Qingyuan Sun, Rijun Xiao, Weixia Peng, Jianping Wang, Hui Peng, Yawei Zhang, Peng Duan, Meiying Zhang, Jianying Liu, Qingmei Huang, Xuefeng Li, Yan Bao, Tianshu Zeng, Kun Wang, Li Qin, Chaoming Wu, Chunying Deng, Chenghu Huang, Shuang Yan, Wei Zhang, Meizi Li, Li Sun, Yanjun Wang, HongMei Li, Guang Wang, Shuguang Pang, Xianling Zheng, Haifang Wang, Fujun Wang, Xiuhai Su, Yujin Ma, Wei Zhang, Ziling Li, Zuoling Xie, Ning Xu, Lin Ni, Li Zhang, Xiangqun Deng, Tianrong Pan, Qijuan Dong, Xiaohong Wu, Xingping Shen, Xin Zhang, Qijing Zou, Chengxia Jiang, Jue Xi, Jianhua Ma, Jingchao Sun, Li Yan
BACKGROUND: Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become firmly established in treatment algorithms and national guidelines for improving glycemic control in type 2 diabetes mellitus (T2DM).To report the findings from a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial, which was designed to assess the efficacy and safety of a novel DPP-4 inhibitor fotagliptin in treatment-naive patients with T2DM. METHODS: Patients with T2DM were randomized to receive fotagliptin (n = 230), alogliptin (n = 113) or placebo (n = 115) at a 2:1:1 ratio for 24 weeks of double-blind treatment period, followed by an open-label treatment period, making up a total of 52 weeks...
October 9, 2023: BMC Medicine
#15
JOURNAL ARTICLE
Osama A Mohammed
Hepatic fibrosis arising from chronic liver injury is characterized by dysregulated healing, including hepatic stellate cell activation and excessive deposition of extracellular matrix proteins. Administration of the hepatotoxin thioacetamide (TAA) induces liver injury coupled to fibrogenesis in rodents, mimicking aspects of human disease. Alogliptin is a highly selective inhibitor of dipeptidyl peptidase-4 with purported antifibrotic actions. We investigated the protective effects of alogliptin against TAA-mediated hepatic fibrosis in rats...
September 25, 2023: Pathology, Research and Practice
#16
JOURNAL ARTICLE
Tomoya Mita, Naoto Katakami, Hidenori Yoshii, Tomio Onuma, Hideaki Kaneto, Takeshi Osonoi, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yutaka Umayahara, Tsunehiko Yamamoto, Hiroki Yokoyama, Nobuichi Kuribayashi, Hideaki Jinnouchi, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada
We previously reported in the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A) that alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, attenuated the progression of carotid atherosclerosis in subjects with type 2 diabetes and no history of cardiovascular disease. This extension study of the SPEAD-A trial investigated whether early alogliptin initiation improved long-term cardiovascular outcomes. The SPEAD-A trial randomized 341 subjects with type 2 diabetes to either alogliptin or conventional treatment to investigate the effects of alogliptin on atherosclerosis...
September 5, 2023: Scientific Reports
#17
JOURNAL ARTICLE
Abeer Rashad Derar, Neven Ahmed, Emad Mohamed Hussien
Herein, we report on the development of disposable screen printed carbon, nanostructure thin film Au/Pt and Pt/Pt all-solid state potentiometric sensors for some antidiabetic compounds called glibtins. The electrodes showed excellent calibration curves (1 × 10-5 -1 × 10-2 M) for alogliptin, saxagliptin and vildagliptin. The electrodes were fully characterized with respect to potential stability, dynamic response time, detection limit, effect of pH and interference according to the IUPAC recommendation...
July 16, 2023: BMC chemistry
#18
JOURNAL ARTICLE
Manal S Elmasry, Wafaa S Hassan, Hanan A Merey, Israa M Nour
A novel, sensitive, and green micellar UPLC method was proposed and validated for the simultaneous determination of four hypoglycemic agents used in type II diabetes mellitus treatment namely, pioglitazone, alogliptin, glimepiride, and vildagliptin. The developed UPLC method was successfully applied for quantitative analysis of these drugs in bulk, in pharmaceutical formulations, and in spiked human plasma. Chromatographic separation was carried out on a Kinetex® 1.7 μm XB-C18 100 Å (50 × 2...
July 12, 2023: BMC chemistry
#19
JOURNAL ARTICLE
Jenny Dimakos, Ying Cui, Robert W Platt, Christel Renoux, Kristian B Filion, Antonios Douros
Dipeptidyl peptidase-4 inhibitors (DPP-4i) interact with sulfonylureas to increase their risk of hypoglycemia. Our population-based study assessed whether intraclass pharmacologic heterogeneity among sulfonylureas (long- vs. short-acting) and DPP-4i (peptidomimetic vs. non-peptidomimetic) modifies this interaction. We conducted a cohort study using the UK's Clinical Practice Research Datalink Aurum linked to hospitalization and vital statistics data. We assembled a cohort of patients initiating sulfonylureas (2007-2020)...
September 2023: Clinical Pharmacology and Therapeutics
#20
Teresa Del Rio, Manveer Ubhi, Luis E Irizarry Nieves, Basilides Fermin, Kala Sury
Drug-induced pancreatitis occurs rarely but should be considered when more common causes have been ruled out. While simple to treat, mortality increases should it progress to a necrotizing process. Here, we present the case of a patient simultaneously using two drugs associated with pancreatitis, which we considered acted synergistically and consequently worsened the patient's outcome.
April 2023: Curēus
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
